Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.
Tomefa E AsempaAbigail K KoisChristian M GillDavid P NicolauPublished in: The Journal of antimicrobial chemotherapy (2022)
Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.
Keyphrases
- gram negative
- klebsiella pneumoniae
- multidrug resistant
- acinetobacter baumannii
- end stage renal disease
- electronic health record
- escherichia coli
- ejection fraction
- newly diagnosed
- chronic kidney disease
- big data
- drug resistant
- peritoneal dialysis
- machine learning
- deep learning
- artificial intelligence
- cystic fibrosis
- patient reported outcomes